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Abstract 
Carvedilol, a drug available as a racemic mixture, is eliminated as 
hydroxyphenylcarvedilol (OHC) by CYP2D6 and O-desmethylcarvedilol (DMC) by 
CYP2C9 followed by conjugation to glucuronides. In contrast to other -adrenergic 
receptor antagonists, carvedilol does not induce insulin resistance or worsen 
glycaemic control in the diabetic hypertensive patients. This study aims to 
investigate the implications of type 2 diabetes (T2DM) on the pharmacokinetics of 
carvedilol enantiomers using an integrated population pharmacokinetic modelling 
approach. In total, 14 T2DM patients with good glycaemic control receiving 
standard doses of metformin and glibenclamide were evaluated along with a 
control group of 13 healthy subjects. Serial blood samples were collected up to 24 
hours after administration of a single 25 mg dose of racemic carvedilol. A 
multicompartmental population pharmacokinetic model describing the 
enantioselective disposition of the parent compound, OHC and DMC was developed 
in NONMEM v7.2. Even though data are limited, it appears that despite inhibition of 
CYP2C9 by long-term glibenclamide administration to T2DM patients, overall there 
is no differencs in the total clearance of carvedilol when compared to healthy  
volunteers (43.1 vs 45.9 L/h for (S)-(-)-carvedilol and 29.0 vs 33.1 L/h for (R)-(+)-
carvedilol). These results provide evidence for a compensatory mechanism to the 
inhibition of CYP2C9, with higher contribution of CYP2D6 to the elimination of 
carvedilol. Therefore, no dose adjustment for carvedilol is recommended in T2DM 
patients receiving glibenclamide and metformin. 
